Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831

Cancer

Volumn 119, Issue 13, 2013, Pages 2447-2454

  Crozier, Jennifer A ^a   Moreno Aspitia, Alvaro ^a   Ballman, Karla V ^b   Dueck, Amylou C ^c   Pockaj, Barbara A ^c   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

adjuvant therapy; body mass index; obesity; trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OBESITY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879094046     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28051     Document Type: Article

References (35)

1. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894:i-xii, 1-253.
2. Ballard-Barbash R, Hunsberger S, Alciati MH, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst. 2009; 101: 630-643.
3. Ogden CL, Carroll MD, Kit BK, Flegal KM,. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012; 307: 483-490.
4. Protani M, Coory M, Martin JH,. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 123: 627-635.
5. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D,. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study [serial online]. BMJ. 2007; 335: 1134.
6. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002; 13: 741-751.
7. Ewertz M, Gray KP, Regan MM, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial. J Clin Oncol. 2012; 30: 3967-3975.
8. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A,. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer. 2009; 124: 698-712.
9. Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A,. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer. 2006; 119: 1683-1689.
10. Loi S, Milne RL, Friedlander ML, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1686-1691.
11. Haakinson DJ, Leeds SG, Dueck AC, et al. The Impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol. 2012; 19: 3012-3018.
12. Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012; 118: 5937-5946.
13. Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N, Edge SB,. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. 2011; 117: 4132-4140.
14. Phipps AI, Buist DS, Malone KE, et al. Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer. Ann Epidemiol. 2012; 22: 340-348.
15. Phipps AI, Chlebowski RT, Prentice R, et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20: 454-463.
16. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002; 77: 148-154.
17. Gee JM, Robertson JF, Gutteridge E, et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer. 2005; 12 (suppl 1): S99-S111.
18. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011; 29: 4491-4497.
19. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-postive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011; 29: 3366-3373.
20. Mosteller RD,. Simplified calculation of body-surface area [letter]. N Engl J Med. 1987; 317: 1098.
21. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012; 379: 432-444.
22. Chlebowski RT,. Obesity and breast cancer outcome: adding to the evidence. J Clin Oncol. 2012; 30: 126-128.
23. Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011; 29: 25-31.
24. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat. 2002; 74: 65-76.
25. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol. 2012; 30: 164-171.
26. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003; 95: 1218-1226.
27. Potischman N, Swanson CA, Siiteri P, Hoover RN,. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst. 1996; 88: 756-758.
28. Probst-Hensch NM, Steiner JH, Schraml P, et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res. 2010; 16: 1025-1032.
29. Surmacz E,. Obesity hormone leptin: a new target in breast cancer [serial online]? Breast Cancer Res. 2007; 9: 301.
30. Kabat GC, Kim M, Caan BJ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 2009; 125: 2704-2710.
31. Roberts DL, Dive C, Renehan AG,. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010; 61: 301-316.
32. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ,. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65: 11118-11128.
33. Goodwin PJ, Ennis M, Fantus IG, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. 2005; 23: 6037-6042.
34. Centers for Disease Control and Prevention. Overweight and Obesity: The Obesity Epidemic. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
35. Kushi LH, Doyle C, McCullough M, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012; 62: 30-67.